FIG. 3.

Effect of test compounds against VSV-G-pseudotyped HIV-1. C8166 cells were infected with GFP-encoding, env-deleted HIV-1 pseudotyped with envelope VSV-G and treated with different compounds at different concentrations. The letters on the x axis represent different concentrations of the respective compounds (in μg/ml, for AMD3100, A = 0, B = 0.008, C = 0.04, D = 0.2, E = 1, and F = 5; for PRM-A, A = 0, B = 0.08, C = 0.4, D = 2, E = 10, and F = 50; for HHA, A = 0, B = 0.16, C = 0.8, D = 4, E = 20, and F = 100; for UC781, A = 0, B = 0.0016, C = 0.008, D = 0.04, E = 0.2, and F = 1; for nevirapine, A = 0, B = 0.0008, C = 0.004, D = 0.02, E = 0.1, and F = 0.5). The infected cells were assayed for GFP expression at 48 h postinfection. One hundred percent of GFP expression for each compound was defined as that for the control culture without the compound added.